|
WO1999061032A1
(en)
*
|
1998-05-25 |
1999-12-02 |
Nippon Shinyaku Co., Ltd. |
Process for producing composite preparation containing nucleic acid
|
|
WO2000044914A1
(en)
*
|
1999-01-28 |
2000-08-03 |
Medical College Of Georgia Research Institute, Inc. |
Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
|
|
EP1097993A3
(en)
*
|
1999-11-05 |
2004-01-07 |
National Institute of Advanced Industrial Science and Technology |
Functional ribozyme chimeric molecules capable of sliding
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
CA2474822A1
(en)
*
|
2002-02-07 |
2003-08-14 |
University Of Utah Research Foundation |
Method for creating and using a treatment protocol
|
|
US20040180438A1
(en)
*
|
2002-04-26 |
2004-09-16 |
Pachuk Catherine J. |
Methods and compositions for silencing genes without inducing toxicity
|
|
AU2003266014B2
(en)
|
2002-05-06 |
2009-05-14 |
Alnylam Pharmaceuticals, Inc. |
Methods for delivery of nucleic acids
|
|
US20030235916A1
(en)
*
|
2002-06-14 |
2003-12-25 |
Monahan Sean D. |
Novel methods for the delivery of polynucleotides to cells
|
|
EP1540004A4
(en)
*
|
2002-07-31 |
2007-10-03 |
Nucleonics Inc |
DOUBLE-STRING RNA STRUCTURES AND CONSTRUCTS AND METHOD FOR THE PRODUCTION AND USE THEREOF
|
|
WO2004073631A2
(en)
*
|
2003-02-14 |
2004-09-02 |
Combinatorx, Incorporated |
Combination therapy for the treatment of neoplasms
|
|
BRPI0411219A
(pt)
|
2003-06-12 |
2006-07-18 |
Nucleonics Inc |
seqüências de hbv e hcv conservadas úteis para silenciamento de gene
|
|
TW200613554A
(en)
|
2004-06-17 |
2006-05-01 |
Wyeth Corp |
Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
|
|
ES2362670T3
(es)
|
2004-09-24 |
2011-07-11 |
Alnylam Pharmaceuticals, Inc |
Orientación a intermedios de replicación de hebra no codificante de virus monocatenarios por arni.
|
|
WO2006069064A2
(en)
|
2004-12-22 |
2006-06-29 |
Nucleonics, Inc. |
Conserved hbv and hcv sequences useful for gene silencing
|
|
HUE026303T2
(hu)
|
2005-07-25 |
2016-06-28 |
Emergent Product Dev Seattle |
B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
|
|
CN105837690A
(zh)
*
|
2006-06-12 |
2016-08-10 |
新兴产品开发西雅图有限公司 |
具有效应功能的单链多价结合蛋白
|
|
DK2041270T3
(da)
|
2006-07-13 |
2014-01-27 |
Wyeth Llc |
Fremstilling af glycoproteiner
|
|
DK2094086T3
(da)
*
|
2006-11-08 |
2013-11-25 |
Veritas Bio LLC |
Indgivelse in vivo af dobbeltstrenget rna til en målcelle
|
|
JP2010532764A
(ja)
*
|
2007-07-06 |
2010-10-14 |
トゥルビオン・ファーマシューティカルズ・インコーポレーテッド |
Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド
|
|
AU2009234277B2
(en)
|
2008-04-11 |
2014-12-04 |
Aptevo Research And Development Llc |
CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
|
DK2427472T3
(en)
|
2009-05-05 |
2016-09-12 |
Miragen Therapeutics |
Lipophilic polynukleotidkonjugater
|
|
SG176716A1
(en)
|
2009-06-08 |
2012-01-30 |
Miragen Therapeutics |
CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS
|
|
WO2011121074A1
(en)
|
2010-04-01 |
2011-10-06 |
Pharmanest Ab |
Thermogelling anaesthetic compositions
|
|
AU2011323085B2
(en)
|
2010-11-05 |
2014-10-30 |
Miragen Therapeutics |
Base modified oligonucleotides
|
|
US8642751B2
(en)
|
2010-12-15 |
2014-02-04 |
Miragen Therapeutics |
MicroRNA inhibitors comprising locked nucleotides
|
|
AU2012242761A1
(en)
|
2011-04-12 |
2013-10-31 |
Beth Israel Deaconess Medical Center, Inc. |
Micro-RNA inhibitors and their uses in disease
|
|
US9018188B2
(en)
|
2011-09-13 |
2015-04-28 |
Ottawa Hospital Research Institute |
MicroRNA inhibitors
|
|
JP6208228B2
(ja)
|
2012-06-21 |
2017-10-04 |
ミラゲン セラピューティクス， インコーポレイテッド |
ロックド核酸モチーフを含むオリゴヌクレオチドベースの阻害剤
|
|
EP2970968B1
(en)
|
2013-03-15 |
2018-01-10 |
Miragen Therapeutics, Inc. |
Bridged bicyclic nucleosides
|
|
US10172916B2
(en)
|
2013-11-15 |
2019-01-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating heart failure with agonists of hypocretin receptor 2
|
|
WO2015074010A2
(en)
|
2013-11-18 |
2015-05-21 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods for cardiac regeneration
|
|
AU2015301221B2
(en)
|
2014-08-04 |
2020-07-02 |
MiRagen Therapeutics, Inc. |
Inhibitors of MYH7B and uses thereof
|
|
RU2712511C2
(ru)
|
2014-09-08 |
2020-01-29 |
Мираген Терапеутикс, Инк. |
Миметики mir-29 и пути их применения
|
|
EP3247716A4
(en)
|
2015-01-20 |
2018-10-17 |
Miragen Therapeutics, Inc. |
Mir-92 inhibitors and uses thereof
|
|
RU2718534C2
(ru)
|
2015-06-05 |
2020-04-08 |
Мираджен Терапьютикс, Инк. |
Ингибиторы mir-155 для лечения кожной t-клеточной лимфомы (ctcl)
|
|
WO2017053469A2
(en)
|
2015-09-21 |
2017-03-30 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
|
US10357543B2
(en)
|
2015-11-16 |
2019-07-23 |
Ohio State Innovation Foundation |
Methods and compositions for treating disorders and diseases using Survival Motor Neuron (SMN) protein
|
|
NZ749593A
(en)
|
2016-06-20 |
2025-10-31 |
Univ Leland Stanford Junior |
Circular rnas and their use in immunomodulation
|
|
UY37376A
(es)
|
2016-08-26 |
2018-03-23 |
Amgen Inc |
Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso
|
|
ES2659845B1
(es)
|
2016-09-19 |
2019-01-04 |
Univ Valencia |
Modulación de microRNAs contra la distrofia miotónica tipo 1 y antagonistas de microRNAs para ello
|
|
UY38003A
(es)
|
2017-12-12 |
2019-06-28 |
Amgen Inc |
Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas
|
|
JP7318166B2
(ja)
|
2018-03-14 |
2023-08-01 |
ベス イスラエル デアコネス メディカル センター |
マイクロｒｎａ２２の阻害剤
|
|
CN113166761B
(zh)
|
2018-12-10 |
2025-09-09 |
美国安进公司 |
用于抑制pnpla3表达的rnai构建体
|
|
KR20210102313A
(ko)
|
2018-12-10 |
2021-08-19 |
암젠 인크 |
화학적으로 변형된 RNAi 작제물 및 이의 용도
|
|
US20220307022A1
(en)
|
2019-05-30 |
2022-09-29 |
Amgen Inc. |
Rnai constructs for inhibiting scap expression and methods of use thereof
|
|
AU2020329286A1
(en)
|
2019-08-13 |
2022-03-17 |
Amgen Inc. |
RNAi constructs for inhibiting SLC30A8 expression and methods of use thereof
|
|
AU2020399636A1
(en)
|
2019-12-09 |
2022-06-02 |
Amgen Inc. |
RNAi constructs and methods for inhibiting LPA expression
|
|
WO2021234607A1
(en)
|
2020-05-20 |
2021-11-25 |
St. Jude Children's Research Hospital |
Detection of alzheimer's disease using specific biomarkers
|
|
KR20240004092A
(ko)
|
2020-06-01 |
2024-01-11 |
암젠 인크 |
Hsd17b13 발현을 억제하기 위한 rnai 작제물 및 이의 사용 방법
|
|
EP3929295A1
(en)
|
2020-06-26 |
2021-12-29 |
Universitat Pompeu Fabra |
Artificial rnas for modulating rna fragments
|
|
CN116194119A
(zh)
|
2020-08-13 |
2023-05-30 |
美国安进公司 |
用于抑制MARC1表达的RNAi构建体和方法
|
|
MX2023005198A
(es)
|
2020-11-05 |
2023-05-16 |
Amgen Inc |
Metodos para tratar la enfermedad cardiovascular aterosclerotica con constructos de iarn dirigidos a lpa.
|
|
WO2023278295A1
(en)
|
2021-06-29 |
2023-01-05 |
The Broad Institute, Inc. |
Compositions and methods for ameliorating anterodorsal thalamus hyperexcitability
|
|
WO2023059629A1
(en)
|
2021-10-05 |
2023-04-13 |
Amgen Inc. |
Compositions and methods for enhancing gene silencing activity of oligonucleotide compounds
|
|
MX2024004913A
(es)
|
2021-10-22 |
2024-05-06 |
Amgen Inc |
Constructos de arni para inhibir la expresion de gpam y metodos de uso de los mismos.
|
|
PE20250754A1
(es)
|
2022-07-25 |
2025-03-13 |
Amgen Inc |
Construcciones de arni y metodos para inhibir la expresion de fam13a
|
|
EP4353823A1
(en)
|
2022-10-12 |
2024-04-17 |
Resalis Therapeutics S.r.l. |
Inhibitors of micro-rna 22
|
|
IL321194A
(en)
|
2022-12-16 |
2025-07-01 |
Amgen Inc |
RNA interference constructs for inhibiting TTR expression and methods for using them
|